2BBBullish & Bearish
Precision BioSciences, Inc. (DTIL) trades on NASDAQ. It operates in the Health Care sector, Biotechnology industry. Its current 2BB score is 39 out of 100.
Precision BioSciences, Inc. is a publicly traded American clinical stage gene editing company headquartered in Durham, North Carolina. Founded in 2006, Precision is focused on developing both in vivo and ex vivo gene editing therapies using its proprietary "ARCUS" genome editing platform.
Precision BioSciences, Inc.’s current 2BB score is 39 out of 100, built from the signal categories below.
| Signal | Score | Reading |
|---|---|---|
| Activity | 43 | Moderate |
| Momentum | 30 | Weakening |
| Financial strength | 20 | Weak |
| Quality | 80 | Very Strong |
| Risk | 46 | Moderate |
| Founded | 2006 |
| Employees | 67 |
| 52-week range | $3.53 – $9.62 |
| Report date | EPS actual | EPS estimate | Revenue actual | Revenue estimate |
|---|---|---|---|---|
| 2026-11-02 | — | -0.7589 | — | $1.12M |
| 2026-08-06 | — | -0.8058 | — | $1.15M |
| 2026-05-05 | -0.75 | -0.6681 | $10.84M | $4.13M |
| 2026-03-12 | 1.05 | -0.5457 | $34.20M | $9.26M |